中国P站

Abstract

Bioequivalence studies are critical for demonstrating drug product interchangeability by assessing pharmacokinetic equivalence. Regulatory agencies provide stringent guidelines, often utilizing dissolution testing and statistical analysis. Advances include novel statistical methods and in vitro data. The Biopharmaceutics Classification System (BCS) may allow for study waivers. Complex drug products and specialized delivery systems require tailored approaches. Pharmacokinetics underpins these assessments, informing interchangeability and post-approval monitoring. Future research focuses on innovation and quality assurance, while food effects remain a relevant design consideration.